Dynamics of Plasma Gonadotropin and Sex Steroid Release in Polycystic Ovarian Disease After Pituitary Ovarian Inhibition with an Analog of Gonadotropin-Releasing Hormone*
- 1 May 1987
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 64 (5) , 980-985
- https://doi.org/10.1210/jcem-64-5-980
Abstract
To assess the dynamics of the suppression and recovery of plasma gonadotropins and sex steroids during and after inhibition of pituitary-ovarian function by a long-acting agonist GnRH-analog (GnRH-A), eight patients with polycystic ovarian disease were treated with 12 .mu.g/kg .cntdot. day GnRH-A for 56 consecutive days. In response to GnRH-A, these patients had a sharp and pronounced decline of their initially elevated immunoreactive LH and bioactive LH (bioLH) levels. Plasma immunoreactive FSH levels declined more rapidly than did bioLH, but the FSH decline was less sustained. Plasma testosterone, androstenedione, and estrone (E1) levels also declined during GnRH-A administration. The pattern of plasma androgen decrease resembled that of bioLH. There was a positive correlation between bioLH and the two androgens (r = 0.85; P < 0.05, by Spearman''s rank correlation, for both hormones). Cessation of GnRH-A administration was followed by prompt progressive increase in gonadotropin and androgen concentration to pretreatment values. FSH recovered faster than bioLH. BioLH plasma concentrations reached pretreatment values by day 28. The recovery of plasma androstenedione and testosterone levels correlated positively with that of bioLH. Although plasma E1 levels were higher during the recovery period than during treatment, they never reached the concentrations found during the basal period, whereas estradiol concentrations were slightly but not significanly higher than those in the basal period. As a consequence, the E1 to estradiol ratio, very high in the basal period, approximated unity during recovery. These data indicate that hyperandrogenism in polycystic ovarian disease is gonadotropin dependent and accompanied by a relative abundance of LH bioactivity basally and during GnRH-A administration. Thus, the relative increase in bioLH secretion appears to be independent of the rate of gonadotropin secretion and the circulating sex steroid concentrations.This publication has 13 references indexed in Scilit:
- Steroid Secretion in Polycystic Ovarian Disease after Ovarian Suppression by a Long-Acting Gonadotropin-Releasing Hormone Agonist*Journal of Clinical Endocrinology & Metabolism, 1983
- Gonadotropin-Releasing Hormone Modulation of Its Own Pituitary Receptors: Evidence for Biphasic Regulation*Endocrinology, 1982
- Enhanced Disparity of Gonadotropin Secretion by Estrone in Women with Poly cystic Ovarian Disease*Journal of Clinical Endocrinology & Metabolism, 1982
- Adrenal Function in Normal Women and Women with the Poly cystic Ovary Syndrome*Journal of Clinical Endocrinology & Metabolism, 1979
- INHIBITORY EFFECTS ON GONADOTROPHIN SECRETION AND GONADAL FUNCTION IN MEN DURING CHRONIC TREATMENT WITH A POTENT STIMULATORY LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUEActa Endocrinologica, 1979
- Pituitary-Ovarian Relationships in Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 1977
- The Effects of Ovarian Wedge Resection on Circulating Gonadotropin and Ovarian Steroid Levels in Patients with Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 1976
- Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.Journal of Clinical Investigation, 1976
- Idiopathic Hirsutism — An Ovarian AbnormalityNew England Journal of Medicine, 1976
- CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMENJournal of Clinical Endocrinology & Metabolism, 1961